INNOVENT ANNOUNCES IBI363 (PD-1/IL-2Α-BIAS BISPECIFIC FUSION PROTEIN) RECEIVED THIRD NMPA BREAKTHROUGH THERAPY DESIGNATION FOR MSS/PMMR METASTATIC COLORECTAL CANCER

Reuters · 2d ago

Please log in to view news